Lord, Abbett & Co
RCUS icon

Lord, Abbett & Co’s Arcus Biosciences RCUS Stock Holding History

Lord, Abbett & Co’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-304,343
Closed -$4.24M – 817
2018
Q3 		$4.24M Buy
304,343
+8,979
+3% +$115K 0.01% 755
2018
Q2 		$3.62M Sell
295,364
-5,330
-2% -$83.6K 0.01% 781
2018
Q1 		$4.64M Buy
+300,694
New +$5.01M 0.01% 742

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's RCUS Position: Q4 2018 in Review

Lord, Abbett & Co sold out of Arcus Biosciences (RCUS) in Q4 2018, closing a stake of 304,343 shares — an estimated $4.24M sold.

Lord, Abbett & Co first reported a position in RCUS in Q1 2018 and held it in 3 quarters. The position peaked at $4.64M in Q1 2018. 67 funds tracked by Wall St. Rank hold RCUS as of Q4 2018.

  • Lord, Abbett & Co reported no remaining Arcus Biosciences position as of Q4 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 304,343 Arcus Biosciences shares in Q4 2018, an estimated $4.24M.
  • Lord, Abbett & Co first reported a position in Arcus Biosciences in Q1 2018 and held it in 3 quarters.
  • Lord, Abbett & Co's Arcus Biosciences position peaked at $4.64M in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2018.

Based on Lord, Abbett & Co's 13F filing for Q4 2018, filed 14 Feb 2019.